Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.

被引：6

作者：

Grivas, Petros ^{[1
,2
]}

Barata, Pedro C. ^{[3
]}

Moon, Helen H. ^{[4
]}

Gupta, Shilpa ^{[5
]}

Hutson, Thomas E. ^{[6
]}

Sternberg, Cora N. ^{[7
]}

Brown, Jason ^{[8
]}

Dave, Vaidehi ^{[9
]}

Downey, Chad ^{[10
]}

Shillington, Alicia C. ^{[11
]}

Katzenstein, Howard ^{[12
]}

Kirker, Melissa

Hanson, Sarah

Liu, Frank X.

Morris, Valerie A.

Bhanegaonkar, Abhijeet

Sonpavde, Guru P.

机构：

[1] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Univ Hosp Seidman, Canc Ctr, Cleveland, OH USA

[4] Kaiser Permanente, Riverside, CA USA

[5] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA

[6] Texas Oncol, Dallas, TX USA

[7] Weill Cornell Med, Hematol Oncol, New York, NY USA

[8] RTI Hlth Solut, Res Triangle Pk, NC USA

[9] EPI Q Inc, Oak Brook, IL USA

[10] EMD Serono, Rockland, MA USA

[11] Pfizer, New York, NY USA

[12] AdventHlth Med Grp, Orlando, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-492-3532-2370-7650-2700; 283-183-138-12268; 130-231; 261-492-11294; 261-492-3532-2370; 613-135-244-3829; 5; 4; 3; 2; 1880; 62; 295; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.697

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：697 / 697

页数：1

共 50 条

[41] Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study
Zhu, Jingni
Sun, Changjiang
Ren, Yuanyuan
Yu, Xinnian
Sun, Zijian
Sun, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.
Nizam, Amanda
Kearney, Mairead
Morris, Valerie A.
Mahmoudpour, Seyed Hamidreza
Lobo, Carroline
Hoffman, Jason
Iliev, Ilian
Yerram, Prakirthi
Guinter, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[43] Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
Chubenko, Viacheslav
Baklanova, Olga
Kalpinskiy, Alexey
Safina, Sufiia
Lebedinets, Andrey
Shkurat, Alexey
Parsadanova, Elvira
Turganova, Maria
Petkau, Vladislav
Tovbik, Natalya
Tkacheva, Elena
Anzhiganova, Yulia
Novikova, Olga
Bragina, Varvara
Zukov, Ruslan
Tsimafeyeu, Ilya
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 117 - 117
[44] AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Barthelemy, P.
Loriot, Y.
Flechon, A.
Goupil, M. Gross
Voog, E.
Eymard, J-C.
Lorgis, V.
Pouessel, D.
Francois, L.
Sajous, C.
Bouju, D. Chocteau
Guillot, A.
Long, J.
Amela, E.
Josse, C.
Solbes, M-N.
Lambert, P.
Thibault, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1211 - S1212
[45] Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
Barthelemy, Philippe
Loriot, Yohann
Thibault, Constance
Gross-Goupil, Marine
Eymard, Jean Christophe
Voog, Eric
Abraham Jaillon, Christine
Le Moulec, Sylvestre
Chasseray, Matthieu
Gobert, Aurelien
Auberger, Benjamin
Viala, Caroline
Cabart, Mathilde
Kazan, Eyad
Lorgis, Veronique
Hilgers, Werner
Josse, Constant
Lambert, Prisca
Solbes, Marie-Noelle
Flechon, Aude
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 561 - 561
[46] Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan
Shindo, Tetsuya
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (08) : 867 - 868
[47] First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Preliminary results of the prospective CARAT registry
Goebell, P. J.
Radkowski, R.
Mueller, L.
Ghasemi, U.
Gruenwald, V.
Deger, S.
Andres-Pons, A.
Lennartz, C.
Jaenicke, M.
Gruellich, C.
Staehler, M.
Gratzke, C.
Potthoff, K.
EUROPEAN UROLOGY, 2024, 85 : S1731 - S1731
[48] Real-world data (RWD) with avelumab in patients (pts) with locally advanced or metastatic urothelial cancer (la-mUC): The AVEBLADDER study.
Sotelo, Marta
Pelaez, Mireia
Basterretxea, Laura
Varga, Estrella
Sanchez-Escribano, Ricardo
Pujol, Eduardo
Santander, Carmen
Martinez-Kareaga, Mireia
Arruti Ibarbia, Mikel
Rodriguez Ledesma, Inma
Alvarez-Fernandez, Carlos
Piedra, Pablo
Calderero, Veronica
Lainez, Nuria
Verdun Aguilar, Juan Antonio
Gil-Arnaiz, Irene
Fernandez, Ricardo
Mazas, Cristina
Duran, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Sridhar, Srikala S.
Powles, Thomas
Duran, Miguel A. Climent
Park, Se Hoon
Massari, Francesco
Thiery-Vuillemin, Antoine
Valderrama, Begona P.
Ullen, Anders
Tsuchiya, Norihiko
Aragon-Ching, Jeanny B.
Gupta, Shilpa
Petrylak, Daniel P.
Bellmunt, Joaquim
Wang, Jing
Laliberte, Robert J.
di Pietro, Alessandra
Costa, Nuno
Grivas, Petros
Sternberg, Cora N.
Loriot, Yohann
EUROPEAN UROLOGY, 2024, 85 (02) : 154 - 163
[50] Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
Lista, Alfonso Gomez De Liano
Romero-Laorden, Nuria
Gajate, Pablo
Orta-Ruiz, Alberto
Jimenez, Jesus Garcia-Donas
Miranda, Maria Jose
Estevez, Sergio Vazquez
Molins, Carmen
Pernaut, Cristina
Cordero, Marta Gonzalez
Fernandez, Ovidio
Sanchez, Jose Garcia
Maeso, Iria Gonzalez
Blazquez, Patricia Rodriguez
Reig, Oscar
Maroto-Rey, Pablo
Martin, Almudena
Ramirez, Ignacio
Puente, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)

← 1 2 3 4 5 →